Last reviewed · How we verify
Control group (diosmin)
Diosmin is a flavonoid that improves venous tone and reduces capillary permeability to enhance microcirculation and lymphatic drainage.
Diosmin is a flavonoid that improves venous tone and reduces capillary permeability to enhance microcirculation and lymphatic drainage. Used for Chronic venous insufficiency, Hemorrhoids, Lymphedema.
At a glance
| Generic name | Control group (diosmin) |
|---|---|
| Sponsor | Hanoi Medical University |
| Drug class | Flavonoid/Venoactive agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Diosmin strengthens blood vessel walls by increasing venous tone and reducing capillary fragility, thereby improving blood flow and reducing fluid accumulation in tissues. It also has anti-inflammatory and antioxidant properties that contribute to its vascular protective effects. These mechanisms make it useful in treating venous insufficiency and related circulatory disorders.
Approved indications
- Chronic venous insufficiency
- Hemorrhoids
- Lymphedema
Common side effects
- Gastrointestinal disturbances
- Headache
- Dizziness
Key clinical trials
- A Phase III Clinical Trial Evaluating the Efficacy and Safety of TriThien Duoc Capsules in Grade II Internal Haemorrhoids Patients With Bleeding Compared to Diosmin. (PHASE3)
- Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers (NA)
- Silymarin vs Hesperidin/Diosmin in Fibromyalgia (NA)
- Efficacy of Diosmin and Hesperidin on Early Rehabilitation After Total Knee Arthroplasty
- Randomized Control Trial of Micronized Purified Flavonoid Fraction for Post Operative Treatment in Anal Fistula Surgery (PHASE4)
- Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis (PHASE3)
- The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients (PHASE3)
- Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Control group (diosmin) CI brief — competitive landscape report
- Control group (diosmin) updates RSS · CI watch RSS
- Hanoi Medical University portfolio CI